PainCeptor receives IRAP assistance

Guest Contributor
February 14, 2006

PainCeptor Pharma Corp has received $480,000 in funding from the Industrial Research Assistance Program to further develop its drug development program for pain-related conditions such as arthritis and cancer. The contribution agreement will be used to advance PainCeptor's R&D for the design and synthesis of low molecular weight compounds as part of its ASIC 3 (acid-sensing ion channels) program. The project will see the Montreal-based firm collaborate with a scientific team led Dr Prabhat Arya, at the National Research Council's Steacie Institute for Molecular Sciences in Ottawa. ASICs are key pain sensors within the peripheral nervous system, allowing pain treatment without dealing with the central nervous system. PainCeptor's president/ CEO is Dr Louis Lamontagne....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.